First Analysis Upgrades Anika Therapeutics (ANIK) to "Overweight"


The brokerage currently has a $68.00 price objective on the biotechnology company's stock, up from their prior price objective of $45.00. First Analysis' price objective suggests a potential upside of 0.34% from the stock's previous close.



from Biotech News